BRASTER gained a reputable investor from the health care sector
Tadeusz Wesołowski, PhD, who is an investor engaging in listed companies from the medical and biotechnology sector, as well as his controlled entity, hold jointly over 6% of stake in BRASTER S.A., the owner of a unique technology for supporting breast cancer diagnostics.
On Monday, February 16, the Company was notified that Tadeusz Wesołowski had exceeded the 5% stake threshold in BRASTER S.A. According to the received document, Tadeusz Wesołowski bought 130,000 of the Company’s shares through a transaction performed on February 9. Thus, he increased his stake up to 185,521 shares (he has previously controlled directly and indirectly 55,521 shares), accounting for 6.16% of the share capital of the Company and 6.16% of votes at the General Meeting.
"The decision of Tadeusz Wesołowski to increase his stake in the Company proves that he is deeply convinced of validity of the strategy aiming at offering our breast tester to women in the second half of 2016. Using their long experience, such reputable investors can thoroughly analyse a company in various areas, both from the medical and business perspective, which also reflects reliability of our activities," says President of the Management Board of BRASTER S.A. Marcin Halicki.
According to publicly available data, other shareholders with over 5% stake in Braster include funds controlled by IPOPEMA TFI, DM BOŚ S.A., as well as representatives of the Company’s management: Member of the Supervisory Board Grzegorz Pielak and Vice-President of the Management Board Henryk Jaremek, PhD, Eng. Another shareholder of Braster is President of the Board Marcin Halicki, who, shortly after taking up his position in October last year, bought a total of 58,072 Company’s shares for PLN 420,000, thereby acquiring 1.93% of the BRASTER S.A. share capital and votes at the General Meeting.
At the end of January, the Company filed a request to the Polish Financial Supervision Authority for renewal of proceedings on approval of the Issuing Prospectus. The approval of the prospectus will allow the Company to move its quotations to the main market of the Warsaw Stock Exchange (WSE).